Sofosbuvir is a direct-acting antiviral medicinal product with oral application. It acts as an inhibitor of the hepatitis C virus NS5B RNA polymerase. It is intended for treatment of chronic hepatitis C virus in adult patients in combination with other medicinal products. The benefit of sofosbuvir treatment, the effectiveness and safety of which has been verified in numerous clinical studies, lies not only in higher proportion of achieving SVR. For the first time, successful treatment of hepatitis C virus without the use of interferon has been confirmed. The prevention of graft reinfection in patients waiting for transplantation for hepatitis C is also an advantage, as well as the effectiveness of treatment in patients co-infected with HIV, and the possibility of shorter treatment in regimens which include interferon and reduce the incidence of adverse events.